2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 6, 2017

9:00AM-11:00AM: Abstract Number: 1454

Association of Poor Prognostic Factors with Medication Persistence Among Adult RA Patients within a Community of Rheumatology Clinics

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

9:00AM-11:00AM: Abstract Number: 988

Association of Ultraviolet-B Radiation and Risk of SLE Among Women in the Nurses’ Health Studies

Epidemiology and Public Health Poster II: Rheumatic Diseases Other than Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1622

Associations Among Classification Criteria Items within Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

9:00AM-11:00AM: Abstract Number: 1146

Associations between Gout and Cancer in an Nhanes Cohort

ARHP Metabolic and Crystal Arthropathies Poster

9:00AM-11:00AM: Abstract Number: 1219

Associations between Muscle Mass and Function with Bone Microarchitecture and Bone Strength in Postmenopausal Women

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1271

Associations between Systemic Lupus Susceptibility (SLE) Loci and Anti-Phospholipid Antibody (aPL) Positivity in Childhood-Onset SLE (cSLE)

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster II: Lupus and Related Disorders, Myositis, Scleroderma and Vasculitis

9:00AM-11:00AM: Abstract Number: 964

Atherogenic Potency of Plasma from Persons with Autoimmune Rheumatic Disorders: Comparative Effects on Cholesterol Flux in Human Macrophages

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?

9:00AM-11:00AM: Abstract Number: 1628

Atrial Fibrillation/Flutter Hospitalizations Among Patients with SLE and Diabetes Compared to the General U.S. Medicaid Population

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

9:00AM-11:00AM: Abstract Number: 1182

Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 1617

Autoimmune Diseases in Patients with Cutaneous Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster II: Damage and Comorbidities

9:00AM-11:00AM: Abstract Number: 1745

Autophagic Memory in Stress Experienced Human T Cells

T Cell Biology and Targets in Autoimmune Disease Poster I

9:00AM-11:00AM: Abstract Number: 1551

Avoidance of Physical Activity Leads to Reduced Inflammatory Enthesitis on Ultrasound

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1695

Baseline Characteristics and Outcomes in a Retrospective Cohort of Patients with Systemic Sclerosis Related Interstitial Lung Disease

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1400

Beneficial Effect of Anti-IL-6 Blockade on Insulin Resistance and Insulin Sensitivity in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1571

Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells

Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster II

«Previous Page
1
…
5
6
7
8
9
…
65
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].